Table 3.
Comparison Of Clinical Features And Laboratory Parameters Among The Three Groups In Cohort 1
| Variable | Early-Stage CRC Patients | Healthy Controls | Polyp Controls | P |
|---|---|---|---|---|
| n | 349 | 349 | 336 | |
| Age (years) | 65 (58–72) | 65 (58–72) | 63 (58–70) | 0.260 |
| Sex (male, %) | 196 (56.2%) | 196 (56.2%) | 194 (57.7%) | 0.891 |
| Neutrophils (109/L)a,b | 4.25 (3.35–5.58) | 3.35 (2.77–4.12) | 3.59 (2.92–4.30) | < 0.001 |
| Lymphocytes (109/L)a,b | 1.87 (1.50–2.39) | 2.18 (1.75–2.68) | 2.10 (1.68–2.55) | < 0.001 |
| Platelets (109/L)a,b,c | 249.00 (211.00–313.50) | 202.00 (170.00–233.00) | 221.00 (186.25–258.75) | < 0.001 |
| Monocytes (109/L)a,b,c | 0.52 (0.40–0.67) | 0.38 (0.31–0.48) | 0.47 (0.39–0.57) | < 0.001 |
| NLRa,b,c | 2.14 (1.66–3.23) | 1.57 (1.22–1.96) | 1.69 (1.32–2.25) | < 0.001 |
| PLRa,b,c | 132.12 (102.92–176.62) | 90.70 (74.53–115.95) | 105.24 (82.80–138.50) | < 0.001 |
| LMRa,b,c | 3.66 (2.79–4.89) | 5.74 (4.61–7.09) | 4.51 (3.55–5.85) | < 0.001 |
| CEA (ng/mL)a,b | 3.57 (2.12–8.07) | 1.90 (1.10–2.70) | 1.75 (1.16–2.97) | < 0.001 |
Notes: aAdjusted P < 0.05: CRC patients with early stages vs healthy controls; bAdjusted P < 0.05: CRC patients with early stages vs polyp controls; cAdjusted P < 0.05: polyp controls vs healthy controls.
Abbreviations: CRC, colorectal cancer; NLR, neutrophil-lymphocyte ratio; PLR, platelet-lymphocyte ratio; LMR, lymphocyte-monocyte ratio; CEA, carcinoembryonic antigen.